Department of Medical Oncology, Nanyang Second People's Hospital, Nanyang, China.
Department of Medical Oncology, Nanyang Central Hospital, Nanyang, China.
Sci Rep. 2023 Jul 1;13(1):10690. doi: 10.1038/s41598-023-37862-y.
The aim of this study was to predict tyrosine kinase inhibitors (TKI) plus anti-PD-1 antibodies (TKI-PD-1) efficacy as second-line treatment in advanced hepatocellular carcinoma (HCC) using radiomics analysis. From November 2018 to November 2019, a total of 55 patients were included. Radiomic features were obtained from the CT images before treatment and filtered using intraclass correlation coefficients (ICCs) and least absolute shrinkage and selection operator (LASSO) methods. Subsequently, ten prediction algorithms were developed and validated based on radiomic characteristics. The accuracy of the constructed model was measured through area under the receiver operating characteristic curve (AUC) analysis; survival analysis was performed via Kaplan-Meier and Cox regression analyses. Overall, 18 (32.7%) out of 55 patients had progressive disease. Through ICCs and LASSO, ten radiomic features were entered into the algorithm construction and validation. Ten machine learning algorithms showed different accuracies, with the support vector machine (SVM) model having the highest AUC value of 0.933 in the training cohort and 0.792 in the testing cohort. The radiomic features were associated with overall survival. In conclsion, the SVM algorithm is a useful method to predict TKI-PD-1 efficacy in patients with advanced HCC using images taken prior to treatment.
本研究旨在利用放射组学分析预测酪氨酸激酶抑制剂（TKI）联合抗 PD-1 抗体（TKI-PD-1）作为晚期肝细胞癌（HCC）二线治疗的疗效。本研究共纳入 55 例患者，这些患者均来自于 2018 年 11 月至 2019 年 11 月。在治疗前，从 CT 图像中提取放射组学特征，并通过组内相关系数（ICC）和最小绝对值收缩和选择算子（LASSO）方法进行过滤。然后，基于放射组学特征开发并验证了十种预测算法。通过接受者操作特征曲线（ROC）分析评估所构建模型的准确性；通过 Kaplan-Meier 和 Cox 回归分析进行生存分析。结果显示，55 例患者中共有 18 例（32.7%）出现疾病进展。通过 ICC 和 LASSO，有 10 个放射组学特征被纳入算法构建和验证。十种机器学习算法显示出不同的准确性，支持向量机（SVM）模型在训练队列中的 AUC 值最高，为 0.933，在测试队列中的 AUC 值为 0.792。放射组学特征与总生存期相关。综上，SVM 算法是一种利用治疗前图像预测晚期 HCC 患者 TKI-PD-1 疗效的有效方法。
